FDA's Janet Woodcock: the clinical trials system is 'broken'
The clinical trials system is “broken” and there needs to be new ways to collect and utilize patient data, Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, told a workshop at the National Academies of Sciences, Engineering, and Medicine today.
The comment came at the end of Woodcock’s talk in which she also noted that use of master protocols (protocols for trials that look at multiple therapies in a single disease or a single treatment in multiple diseases) and the development of new clinical trial networks “need to be the future.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.